Table 3.
The oral bioavailability of various insulin-loaded nanoparticle formulations in diabetic rats.
| Nanoparticle formulation | Dose (IU/kg) | Bioavailability (%) | Refs |
|---|---|---|---|
| Alginate/chitosan nanoparticles | 50 | 5.1 ± 2.1 | [39] |
| PLGA/HPMCP-55 nanoparticles | 50 | 6.27 | [20] |
| PLGA/Eudragit RS100 nanoparticles in an enteric-coated capsule | 50 | 9.2 | [20] |
| Carboxylated chitosan-grafted poly(methylmethacrylate) nanoparticles | 25 | 9.7 | [40] |
| Alginate/dextran sulfate nanoparticles | 50 | 10.7 | [41] |
| Poly(ɛ-caprolactone)/Eudragit RS 100 nanoparticles | 50 | 13.2 | [14] |
| Chitosan/poly(γ-glutamic acid) nanoparticles | 30 | 15 | [35] |
| Chitosan/poly(γ-glutamic acid) nanoparticles in an enteric-coated capsule | 30 | 20 | [22] |
| Chitosan/poly(γ-glutamic acid)-DTPA nanoparticles | 30 | 19.7 ± 1.3 | [24] |
| Chitosan/sodium alginate nanoparticles | 10 | 43.6 | [42] |
DTPA = diethylenetriaminepentaacetic acid; PLGA = poly(lactide-co-glycolide).